Which isoforms of IMPDH does mycophenolic acid target in lymphocytes?
Best insight from top research papers
Mycophenolic acid (MPA) targets both IMPDH1 and IMPDH2 isoforms in lymphocytes . MPA inhibits the activity of IMPDH, which is involved in the de novo synthesis of guanosine nucleotides . The inhibition of IMPDH by MPA leads to a reduction in lymphocyte proliferation and contributes to the immunosuppressive effects of MPA . The study by Sara Bremer et al. found that the gene expressions of both IMPDH1 and IMPDH2 were reduced in CD4+ cells after exposure to MPA . Another study by Andrea Griesmacher et al. demonstrated that both MPA and its metabolite MPA glucuronide (MPAG) contribute to the inhibition of both IMPDH isoforms . Therefore, MPA targets both IMPDH1 and IMPDH2 isoforms in lymphocytes, leading to immunosuppression.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
64 Citations | The paper does not provide information about which isoforms of IMPDH mycophenolic acid targets in lymphocytes. |
53 Citations | The paper does not explicitly mention which isoforms of IMP-DH mycophenolic acid targets in lymphocytes. |
35 Citations | The paper does not mention the specific isoforms of IMPDH targeted by mycophenolic acid in lymphocytes. |
| The paper does not provide information about which isoforms of IMPDH mycophenolic acid targets in lymphocytes. | |
21 Citations | The paper does not explicitly mention which isoforms of IMPDH mycophenolic acid targets in lymphocytes. |
Related Questions
How does GLP-1RA impact on lymphocyte?4 answersGLP-1RA has been shown to impact lymphocytes in various ways. GLP-1RAs have been found to have anti-inflammatory effects and can modulate the immune system, targeting different pathways in different tissues. In a study, GLP-1RA liraglutide was found to downregulate the expression of inflammatory genes in peripheral blood mononuclear cells (PBMCs). Another study showed that GLP-1R signaling was decreased in circulating PBMCs of COPD patients, which was associated with decreased interferon (IFN)-γ expression. GLP-1R signaling was also found to be important in controlling mucosal immune responses in the intestine, with GLP-1R agonists reducing cytokine production from activated intraepithelial lymphocytes (IELs). These findings suggest that GLP-1RA therapy can have immunomodulatory effects on lymphocytes, potentially impacting inflammatory responses and immune function.
How does impdh cause cancer?4 answersIMPDH (inosine monophosphate dehydrogenase) is a rate-limiting enzyme involved in nucleotide biosynthesis. Inhibition of IMPDH leads to the depletion of guanine nucleotides, which suppresses the growth of cancer cells. IMPDH inhibition has been shown to have therapeutic value in treating MLL-fusion leukemia, including those with defective p53 signaling. The quest for novel IMPDH inhibitors continues, as currently available inhibitors have unfavorable tolerability profiles. The inhibitor 6-Cl-purine ribotide forms a covalent adduct with the Cys-341 residue of Mycobacterium thermoresistibile IMPDH. Extensive molecular dynamics simulations have revealed the presence of a conserved water molecule in the active site of human IMPDH, which may be exploited to design better inhibitors. Mizoribine, an IMPDH inhibitor, has shown superior antitumor activity compared to mycophenolate mofetil, an FDA-approved IMPDH inhibitor, in tumor models of tuberous sclerosis complex.
Papers that cast doubt on the use of mycophenolic acid to prevent transplant rejection?5 answersMycophenolic acid (MPA) is commonly used to prevent transplant rejection, but there are some papers that cast doubt on its effectiveness. One study found that a higher MPA trough concentration (MPA C₀) or dose was associated with an increased risk of cytopenia, but not with biopsy-proven acute rejection (BPAR). Another study suggested that measuring predose MPA concentrations in peripheral blood mononuclear cells (C0C) could be useful in predicting graft rejection in renal transplant recipients. A review article mentioned that therapeutic drug monitoring for MPA may be helpful in various clinical settings of liver transplantation, indicating that a fixed-dosage regimen might not be suitable. Additionally, a study found that monitoring MPA trough concentration combined with cyclosporine trough concentration was useful in avoiding acute cellular rejection in kidney transplantation patients. Overall, these papers suggest that there may be limitations and variability in the use of MPA to prevent transplant rejection.
What are the papers that show the severity of mycophenolic acids adverse effects?5 answersMycophenolic acid (MPA) has been shown to inhibit the growth of Candida albicans and induce cell cycle arrest with defective cytokinesis. Clinical studies suggest that MPA is associated with impaired wound healing, possibly due to the inhibition of inflammatory response. These findings indicate the potential adverse effects of MPA on cellular processes and wound healing.
How is mycophenolic acid administered?5 answersMycophenolic acid can be administered in various forms. It can be used as a salt or prodrug, such as mycophenolate mofetil (MMF). MMF is available as an ester prodrug of mycophenolic acid and is formulated to improve its bioavailability. Mycophenolic acid can also be administered in the form of a delayed-release formulation called mycophenolate sodium, which delivers the drug to the small intestine without being released into the stomach. Additionally, mycophenolic acid can be formulated as a powder or a lyophilized composition for injection, making it suitable for parenteral administration. The specific dosage regimen and route of administration may vary depending on the indication for use, such as prevention or treatment of transplant rejection and immune-mediated and/or inflammatory diseases.
What is the role of mycophenolic acid in cancer treatment?5 answersMycophenolic acid (MPA) has emerged as a potential anti-cancer compound that inhibits cell division or interferes with the mitotic mechanism. It was discovered during routine screening tests with mould filtrates for activity against mouse fibroblasts. MPA shows promise as a treatment for cancer when used alone or in combination with standard treatments such as chemotherapy and radiotherapy. Additionally, MPA has been found to have a more specific action than general lethality, making it a potential candidate for targeted cancer therapy. Further research is needed to fully understand the role of MPA in cancer treatment and to explore its potential as a therapeutic agent.